A case series demonstrates significant hematologic responses in relapsed AL amyloidosis patients, suggesting talquetamab's potential as a treatment option.
Key Points
83% of patients achieved hematologic response with talquetamab treatment, indicating strong efficacy in a difficult-to-treat population.
Talquetamab was given to patients with advanced organ dysfunction, showing promise as a feasible treatment option.
Retrospective analysis across multiple sites evaluated safety and efficacy in relapsed or refractory AL amyloidosis patients.
The safety profile was manageable, with no unexpected toxicities observed following treatment.